Prestige Consumer Healthcare's shares fell over 11% on May 14, 2026, after the company reported a 5% revenue decline in Q4 2026 and significant supply chain problems, especially affecting its Clear Eyes brand. The North America OTC Eye & Ear Care segment saw a 20.6% revenue drop, while the International OTC segment fell 31.3% year-over-year. These issues were linked to delays and shutdowns at the recently acquired Pillar5 facility. A shareholder rights firm, Hagens Berman, has launched an investigation into whether Prestige misled investors about resolving these supply constraints. Investors who suffered losses are encouraged to report them as the investigation continues.
Christopher Derrick, known for writing on Star Trek: Picard and The Equalizer, premieres his first film as sole writer-director, Moral Dirt, at the Academy Award® Qualifying LA Shorts International Film Festival on August 3, 2026. The 15-minute psych...
Arcutis Biotherapeutics has appointed Chris Peetz to its Board of Directors as of July 15, 2026. Peetz brings extensive experience leading biopharmaceutical companies through growth phases, product development, and strategic acquisitions. His additio...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
